1. Home
  2. PHAR vs PML Comparison

PHAR vs PML Comparison

Compare PHAR & PML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • PML
  • Stock Information
  • Founded
  • PHAR 1988
  • PML 2002
  • Country
  • PHAR Netherlands
  • PML United States
  • Employees
  • PHAR N/A
  • PML N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • PML Investment Managers
  • Sector
  • PHAR Health Care
  • PML Finance
  • Exchange
  • PHAR Nasdaq
  • PML Nasdaq
  • Market Cap
  • PHAR 679.0M
  • PML 545.3M
  • IPO Year
  • PHAR N/A
  • PML N/A
  • Fundamental
  • Price
  • PHAR $9.29
  • PML $8.24
  • Analyst Decision
  • PHAR Strong Buy
  • PML
  • Analyst Count
  • PHAR 3
  • PML 0
  • Target Price
  • PHAR $27.00
  • PML N/A
  • AVG Volume (30 Days)
  • PHAR 6.7K
  • PML 188.0K
  • Earning Date
  • PHAR 03-13-2025
  • PML 01-01-0001
  • Dividend Yield
  • PHAR N/A
  • PML 5.65%
  • EPS Growth
  • PHAR N/A
  • PML N/A
  • EPS
  • PHAR N/A
  • PML N/A
  • Revenue
  • PHAR $285,745,000.00
  • PML N/A
  • Revenue This Year
  • PHAR $20.08
  • PML N/A
  • Revenue Next Year
  • PHAR $9.22
  • PML N/A
  • P/E Ratio
  • PHAR N/A
  • PML N/A
  • Revenue Growth
  • PHAR 30.64
  • PML N/A
  • 52 Week Low
  • PHAR $6.65
  • PML $6.92
  • 52 Week High
  • PHAR $13.20
  • PML $9.46
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 48.44
  • PML 49.58
  • Support Level
  • PHAR $9.37
  • PML $7.97
  • Resistance Level
  • PHAR $10.01
  • PML $8.29
  • Average True Range (ATR)
  • PHAR 0.55
  • PML 0.09
  • MACD
  • PHAR -0.13
  • PML 0.04
  • Stochastic Oscillator
  • PHAR 13.82
  • PML 79.07

About PHAR Pharming Group N.V.

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.

About PML Pimco Municipal Income Fund II of Beneficial Interest

PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.

Share on Social Networks: